Anti-EGFR monoclonal antibody, bispecific antibody thereof, and pharmaceutical composition and use thereof
Anti-EGFR-anti-Met bispecific antibodies constructed using common light chain technology address drug resistance and safety issues, offering effective tumor treatment by inhibiting signaling pathways and promoting endocytosis.
AE202602246AUndeterminedSHANGHAI ALLINK BIOTHERAPEUTICS CO LTD
Patent Information
- Authority / Receiving Office
- AE · AE
- Patent Type
- Applications
- Current Assignee / Owner
- SHANGHAI ALLINK BIOTHERAPEUTICS CO LTD
- Filing Date
- 2024-12-30
AI Technical Summary
Technical Problem
Current EGFR kinase inhibitors face high drug resistance and complex mechanisms in non-small cell lung cancer, with bispecific antibodies targeting EGFR and Met presenting safety risks due to skin toxicity and challenging production methods.
Method used
Development of anti-EGFR-anti-Met bispecific antibodies using common light chain technology to construct '1+1' type antibodies, inhibiting EGF and HGF-induced Akt and ERK phosphorylation, promoting endocytosis, and enhancing ADCC effects.
Benefits of technology
The bispecific antibodies exhibit good antitumor activity with improved safety and efficiency in treating tumors that highly express EGFR and/or Met, including non-small cell lung cancer.
✦ Generated by Eureka AI based on patent content.
Smart Images
Figure ABST_ABST
Abstract
The present invention belongs to the field of biomedicine and relates to an anti-EGFR monoclonal antibody, a bispecific antibody thereof, and a pharmaceutical composition and use thereof. Specifically, the present invention relates to an anti-EGFR antibody or an antigen-binding fragment thereof. The present invention further relates to an anti-EGFR-anti-Met bispecific antibody. The anti-EGFR monoclonal antibody and the bispecific antibody of the present invention have good anti-tumor activity.
Need to check novelty before this filing date? Find Prior Art